CELC vs. RNLX, XGN, DMTK, VCYT, CDNA, VRDN, CSTL, FLGT, SERA, and BDSX
Should you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Renalytix (RNLX), Exagen (XGN), DermTech (DMTK), Veracyte (VCYT), CareDx (CDNA), Viridian Therapeutics (VRDN), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Sera Prognostics (SERA), and Biodesix (BDSX). These companies are all part of the "medical laboratories" industry.
Celcuity (NASDAQ:CELC) and Renalytix (NASDAQ:RNLX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
Celcuity received 320 more outperform votes than Renalytix when rated by MarketBeat users. Likewise, 66.94% of users gave Celcuity an outperform vote while only 32.00% of users gave Renalytix an outperform vote.
Celcuity presently has a consensus price target of $29.25, suggesting a potential upside of 85.13%. Renalytix has a consensus price target of $5.00, suggesting a potential upside of 1,105.40%. Given Renalytix's higher possible upside, analysts clearly believe Renalytix is more favorable than Celcuity.
Renalytix has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Celcuity has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500.
In the previous week, Celcuity had 6 more articles in the media than Renalytix. MarketBeat recorded 8 mentions for Celcuity and 2 mentions for Renalytix. Renalytix's average media sentiment score of 0.96 beat Celcuity's score of 0.21 indicating that Renalytix is being referred to more favorably in the news media.
Celcuity has a net margin of 0.00% compared to Renalytix's net margin of -1,687.80%. Celcuity's return on equity of -61.66% beat Renalytix's return on equity.
63.3% of Celcuity shares are owned by institutional investors. Comparatively, 9.9% of Renalytix shares are owned by institutional investors. 24.3% of Celcuity shares are owned by company insiders. Comparatively, 18.3% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Celcuity beats Renalytix on 9 of the 16 factors compared between the two stocks.
Get Celcuity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celcuity Competitors List
Related Companies and Tools
